XFOR - X4 Pharmaceuticals, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.97 -0.02 (-0.67%)	---	-0.05 (-1.67%)	-0.05 (-1.67%)	0.04 (1.35%)	-0.15 (-5.0%)	-0.04 (-1.34%)	-0.04 (-1.34%)

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -3.47
Diluted EPS:: -3.47
Basic P/E:: -0.8501
Diluted P/E:: -0.8501
RSI(14) 1m:: 73.56
VWAP:: 2.95
RVol:: 0.7372

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	2.85 -0.03 (-1.04%)	Oct 15 15:59
1m	Price increase 1m	2.88 +0.03 (+1.23%)	Oct 15 14:20
1m	Price decrease 1m	2.85 -0.05 (-1.72%)	Oct 15 12:17
1m	Price increase 1m	2.95 +0.04 (+1.37%)	Oct 15 10:29
1m	Price increase 1m	2.96 +0.03 (+1.03%)	Oct 15 10:18